Evidence map›Paper›PMID 40476258›Full record

ReviewWorld journal of biological chemistry2025

Stem cell therapy for Parkinson's disease: A new hope for neural regeneration.

Yasmin Garkani Mokhtari, Irene Varnava, Kosmas Kyrgiannis, Vasiliki Ampatsidou, Dimitrios Giakoumettis

Abstract readReview
In one paragraph

Review in World journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yasmin Garkani MokhtariDepartment of Medicine, Basic Biomedical Sciences, Specialization in Stem Cells, Gene-Cell Therapy, Regenerative Medicine, University of Ioannina, Ioannina 45110, Ipeiros, Greece.
Irene VarnavaDepartment of Medicine, Basic Biomedical Sciences, Specialization in Stem Cells, Gene-Cell Therapy, Regenerative Medicine, University of Ioannina, Ioannina 45110, Ipeiros, Greece.
Kosmas KyrgiannisDepartment of Neurosurgery, Agios Savvas, General Anticancer Oncological Hospital, Athens 11522, Attikí, Greece.
Vasiliki AmpatsidouDepartment of Neurosurgery, Agios Savvas, General Anticancer Oncological Hospital, Athens 11522, Attikí, Greece.
Dimitrios GiakoumettisDepartment of Neurosurgery, Agios Savvas, General Anticancer Oncological Hospital, Athens 11522, Attikí, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons in the substantia nigra that leads to reduced dopamine levels and impaired motor function. Current treatments only provide temporary symptom relief without addressing the underlying neuronal loss. A promising new approach for treating PD is stem cell therapy, particularly induced pluripotent stem cells and human pluripotent stem cells. They have the ability to differentiate into various neural cells, offering potential for neuronal replacement and restoration of brain function. Induced pluripotent stem cells are derived from reprogramming adult cells and present advantages such as genetic compatibility and reduced immune rejection, overcoming ethical concerns associated with embryonic stem cells. Preclinical studies show promising results, demonstrating that stem cells can differentiate into dopaminergic neurons and improve motor function in animal models. These advancements pave the way for clinical trials and potential long-term solutions for patients with PD. This review highlighted the significance of stem cell therapy in neuroregeneration and addressed preclinical successes, challenges in long-term safety, and ethical considerations, with the hope of revolutionizing PD treatment and improving patient outcomes.

Indexed as

Adult stem cellsHuman pluripotent stem cellsInduced pluripotent stem cellsParkinson’s diseaseStem cells

Identifiers

PMID40476258
PMCPMC12136083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.